Medtronic To Promote Amgen’s Osteoporosis Drug
This article was originally published in The Gray Sheet
Under a three-year strategic partnership with Amgen, Medtronic will start promoting Amgen Inc.’s Prolia (denuosumab) to U.S. spine specialists by July 31. Prolia is FDA-approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.